What Lilly’s 48% quarter and Novo’s raised-but-still-shrinking outlook mean for the incretin duopoly

Forty-eight hours, two tables, one category that no longer trades as a single idea. On 4 August, Novo Nordisk reported second-quarter net sales of DKK 78,488 million and raised full-year guidance into a range that still points down. On 5 August, Eli Lilly reported revenue of $22.974 billion, up 48% from a year earlier, and lifted the ceiling. The question the quarter answers is not who won a session. It is who captures the next unit as realized prices fall, orals reach pharmacies, and next-generation assets stop being abstracts.

Volume paid Lilly’s bill

Lilly’s table is blunt. Worldwide revenue was $22.974 billion, versus $15.558 billion a year earlier, driven by a 60% rise in volume and partially offset by a 13% decline in realized prices. United States revenue rose 33% to $14.4 billion on 37% more volume and 3% lower realized prices. Revenue outside the United States rose 80% to $8.6 billion on 113% more volume and 36% lower realized prices. Lilly named the addition of Mounjaro to China’s National Reimbursement Drug List as the primary ex-U.S. price driver.

Worldwide Mounjaro revenue was $9.943 billion, up 91% — $4.8 billion in the United States, up 45%, and $5.2 billion outside it, up 172%. Worldwide Zepbound was $4.928 billion, up 46%; U.S. Zepbound rose 44% to $4.9 billion, “partially offset by lower realized prices, including previously announced reductions in cash-pay prices.” Two brands, roughly $14.9 billion in a quarter. Mounjaro’s growth is now more international than American; Zepbound remains a U.S. obesity product in all but name.

Lilly raised 2026 revenue guidance to $85 billion to $87 billion from $82 billion to $85 billion. Reported earnings per share were $7.94; non-GAAP EPS was $8.38. Both include $3.03 of acquired in-process research-and-development charges, against $0.14 a year earlier. The operating statement shows $2.776 billion of acquired IPR&D in the quarter. That is a real charge. It is not the incretin story. The incretin story is that Lilly can take a 13% realized-price hit, book nearly $2.8 billion of pipeline shopping, and still raise the top line.

A raise that still points down

Novo’s print is the other half of the same market. Reported sales rose 3% at constant exchange rates. Adjusted sales, which strip a DKK 2.6 billion U.S. 340B rebate-provision reversal from the year-ago quarter, rose 7% at CER. Adjusted operating profit was DKK 33,389 million, up 11% at CER. Reported operating profit fell 16% at CER after DKK 6.3 billion of non-cash impairment charges on intangible pipeline assets, including DKK 4.0 billion on monlunabant.

Novo now expects adjusted sales growth and adjusted operating-profit growth for 2026 of 0% to −6% at CER, citing higher GLP-1 product-sales expectations. A Reuters dispatch carried by BNN Bloomberg put the prior range, from 6 May, at −4% to −12% for both lines. The raise is real. The destination is still a decline, or at best a flat year, on the measures Novo is asking the market to use.

The oral is the exhibit Novo wants read. The company said the Wegovy pill had reached more than 5 million prescriptions since launch, and that weekly total prescriptions exceeded 265,000 in the week ending 17 July. Measured by new patient starts, Novo said the Wegovy franchise remained the market leader among branded obesity medications in the United States. Those are commercial facts. They did not convert a declining full-year frame into a growing one.

CNBC, writing after both prints, reported that Wegovy-pill revenue came in slightly below analyst expectations, and that investors punished Novo a day before they sent Lilly shares higher. The same piece, citing Lilly’s earnings presentation, put Lilly at 60.9% of the U.S. obesity-and-diabetes drug market in the second quarter, against Novo’s 38.8%. That split is Lilly’s slide, as reported — not an audited census. It is the number the industry is now arguing from.

Orals are not yet a share statistic

Lilly added Foundayo (orforglipron) to “Key Products” in the second quarter and disclosed $98 million of Foundayo revenue. That is a launch line, not a franchise. It cannot be stacked against Novo’s “more than 5 million prescriptions” and called share. One company is counting dollars in a quarter; the other is counting prescriptions since launch. Different numerators, different clocks.

The next injectable is on a calendar. Lilly said the retatrutide Phase 3 package is complete — obesity, obstructive sleep apnea, and knee osteoarthritis pain — and that it plans to submit a biologics license application to the U.S. FDA in the first quarter of 2027. It also submitted orforglipron for type 2 diabetes in the United States. Novo, in the same week, disclosed that the ZEUS Phase 3 trial of ziltivekimab did not meet its primary endpoint, and took the monlunabant impairment. Lilly is dating a next-generation obesity filing. Novo is writing down a cannabinoid it no longer wants on the books.

What the duopoly is now

GLP-1 demand did not break. Volume is still doing the work — +60% at Lilly, GLP-1 volume growth “across geographies” at Novo. Realized price is now a first-order variable, and the two companies are not equally good at converting a cheaper prescription into a larger P&L. Lilly’s U.S. price, the company said, would have declined by about 9% without rebate-and-discount estimate adjustments. Ex-U.S., China’s list is doing what national reimbursement lists do. Novo’s raise still embeds a year in which adjusted sales may fall.

None of that requires a 2027 category-size forecast. The 2026 tables are enough. One duopolist raised the ceiling on a business still growing at 48%. The other raised guidance into a decline and still had to explain a pill that, by the coverage that followed the print, missed a consensus number by enough to matter to the people who model it. The rest of the year will not be about whether people still want the drugs. It will be about whose volume, at which realized price, shows up in the next two tables.